8-K: United Therapeutics Reports Record 2025 Revenue, Strong Tyvaso Growth

United Therapeutics Corporation announced record full year 2025 revenues of $3.18 billion, an 11% increase over 2024, driven by strong performance in its Tyvaso product line.

Summary

• Full year 2025 revenues reached a record $3.18 billion, reflecting an 11% growth over 2024.
• Fourth quarter 2025 total revenues were $790.2 million, a 7% increase compared to $735.9 million in the fourth quarter of 2024.
• Full year 2025 net income was $1,334.7 million, up from $1,195.1 million in 2024.
• Full year 2025 diluted net income per share was $27.86, an increase from $24.64 in 2024.
• Total Tyvaso revenues grew by 16% to $1,878.2 million for the full year 2025, primarily driven by Tyvaso DPI.
• Tyvaso DPI net product sales increased by 25% to $1,292.5 million for the full year 2025.
• Orenitram revenues grew by 14% to $496.9 million for the full year 2025.
• Research and development expense increased by 14% for the full year 2025 to $550.0 million, mainly due to manufactured organ projects and drug delivery device technologies.
• A $21.7 million impairment charge for property, plant, and equipment was recorded in the second quarter of 2025.
• Litigation accrual related to Sandoz Inc. decreased significantly to $3.0 million in 2025 from $71.1 million in 2024.
• The company executed accelerated share repurchase agreements totaling $2.0 billion, with $1.0 billion in August 2025 and $1.0 billion in March 2024.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong performance, driven by robust product sales and promising clinical pipeline updates, indicating solid operational execution and future growth potential despite some product declines.

Positives

• Achieved record total revenue of $3.18 billion for the full year 2025, marking the fourth consecutive year of record revenue.
• Experienced strong double-digit revenue growth of 11% for the full year 2025.
• Tyvaso DPI demonstrated impressive growth, with full year 2025 sales increasing by 25% to $1,292.5 million.
• Net income and diluted earnings per share significantly increased for both the fourth quarter and full year 2025.
• Anticipates pivotal data from ADVANCE OUTCOMES and TETON-1 clinical programs, which could lead to significant new treatment options and transformational growth.
• Litigation accrual for ongoing litigation with Sandoz Inc. substantially decreased from $71.1 million in 2024 to $3.0 million in 2025.
• Engaged in significant share repurchase programs totaling $2.0 billion, indicating a commitment to returning value to shareholders.

Negatives

• Nebulized Tyvaso revenues decreased by 12% in the fourth quarter of 2025 and marginally for the full year.
• Remodulin net product sales decreased by 5% in the fourth quarter and 2% for the full year 2025.
• Unituxin net product sales decreased by 8% in the fourth quarter and 5% for the full year 2025.
• Recorded a $21.7 million impairment charge to write down the carrying value of certain property, plant, and equipment during the second quarter of 2025.

Risks

• Forward-looking statements are subject to certain risks and uncertainties, such as those described in periodic reports filed with the Securities and Exchange Commission, including the most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K.
• The ultimate amount payable in the ongoing litigation with Sandoz Inc. could be higher or lower than the current accrual of $3.0 million, depending on post-judgment interest and the outcome of appeals.

Future Outlook

The company anticipates that its ADVANCE OUTCOMES and TETON-1 clinical programs are on the cusp of unveiling pivotal data, which could unlock significant new treatment options for patients and launch a period of transformational growth. Management expects to continue delivering durable double-digit revenue growth.

Management Comments

• Martine Rothblatt, Ph.D., Chairperson and CEO: "As we close out another remarkable year with record total revenue for the fourth year in a row, I extend my thanks to our Unitherians whose unwavering commitment to innovation and excellence fuels our mission. Looking ahead, our ADVANCE OUTCOMES and TETON-1 clinical programs are on the cusp of unveiling pivotal data that could unlock significant new treatment options for patients, launching a period of transformational growth for UT."
• Michael Benkowitz, President and COO: "This was an exceptional year for our commercial organization, highlighted by strong double-digit revenue growth and disciplined execution by our teams. Tyvaso continued its impressive trajectory in a growing market where we are steadily increasing our share of voice. Looking ahead, we believe our commercial strength, differentiated therapies, and expanding market opportunities position us well to continue delivering durable double-digit revenue growth."

Industry Context

StockSavvy.ai notes that United Therapeutics' continued strong growth in the pulmonary arterial hypertension (PAH) market, particularly with Tyvaso DPI, demonstrates resilience and market penetration in a competitive rare disease landscape. The company's focus on manufactured organs and organ alternatives positions it at the forefront of innovative, high-impact medical technologies, potentially diversifying its revenue streams beyond traditional pharmaceuticals and aligning with broader trends in regenerative medicine.

Legal Proceedings

• Ongoing litigation with Sandoz Inc., with an accrual of $3.0 million recorded in 2025 (down from $71.1 million in 2024).
• The amount ultimately payable, if any, could be higher or lower than the current accrual depending on post-judgment interest and the outcome of appeals.

Stakeholder Impact

• Shareholders: Positive impact due to record revenues, increased profitability, share repurchase programs, and promising future clinical trial data, suggesting enhanced shareholder value.
• Patients: Potential for significant new treatment options from ADVANCE OUTCOMES and TETON-1 clinical programs, and continued access to differentiated therapies for rare diseases.
• Employees (Unitherians): Acknowledged for their commitment to innovation and excellence, with growth in headcount contributing to increased personnel expenses, indicating continued investment in human capital.

Next Steps

• Unveiling pivotal data from the ADVANCE OUTCOMES clinical program.
• Unveiling pivotal data from the TETON-1 clinical program.
• Continued efforts to deliver durable double-digit revenue growth.
• Host a webcast to discuss fourth quarter and full year 2025 financial results on February 25, 2026, at 9:00 a.m. Eastern Time.

Key Dates

Recommendation

The company delivered record revenues for the fourth consecutive year, driven by robust growth in its key product, Tyvaso DPI. Profitability metrics (net income, EPS) also showed significant improvement. The substantial reduction in litigation accruals and ongoing share repurchase programs further enhance shareholder value. Management's forward-looking statements regarding pivotal clinical trial data for ADVANCE OUTCOMES and TETON-1 suggest a pipeline poised for "transformational growth," indicating strong future prospects. These factors collectively present a compelling investment case.

Keywords

United Therapeutics, UTHR, financial results, Q4 2025, full year 2025, revenue growth, net income, EPS, Tyvaso DPI, pulmonary arterial hypertension, rare diseases, clinical trials, ADVANCE OUTCOMES, TETON-1, organ transplantation, share repurchase, biotechnology, pharmaceuticals